Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Watch SpaceX launch NASA's Pandora exoplanet-studying satellite on Jan. 11 - 2Israel's fractured opposition hands Netanyahu a full term
- 3Shakira's 2026 'Las Mujeres Ya No Lloran' U.S. Tour: How to get tickets, prices, dates and more
- 4Progress Over Perfection: Lessons From Garment Factories Fighting Heat Stress
- 5Finding China: Four Urban areas for a Remarkable Excursion
- Releasing Learning Experiences: A Survey of the \Learning Made Fun\ Instructive Application
- The best overlooked performances of 2025
- 4 Coolers for Present day Kitchens
- Inside Kathy Hilton’s Christmas pajama party: caviar bumps, champagne vending machines and a mansion full of Housewives
- ‘Wu-Tang Forever: The Final Chamber’ tour — How to get tickets, presale times, concert dates and more
- Between 600 to 800 aid trucks entering Gaza daily since start of ceasefire, COGAT confirms
- Vote In favor of Your Favored Comupter Game
- Toilet rats? Washington health officials warn of possible rodents in sewer systems after floods
- No red, no long shorts: The fashion rules Joe Burrows lives by
